Home › Calculator › MRKR Dividend Calculator 2026
MRKR Dividend DRIP Calculator 2026
124.22% YieldHealthcareMarker Therapeutics, Inc. · NASDAQ
Price: $1.61 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When MRKR pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your MRKR snowball 📈
$10,000 in MRKR → $6298158925606.72M in 10 years · $524,434,302,120,995,900.00/month
About Marker Therapeutics, Inc. (MRKR) — Dividend Analysis 2026
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
Compare MRKR with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full MRKR DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open MRKR position with:
🌍 MRKR Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold MRKR.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 124.22% | 121.42% | $12,422 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 105.59% | 102.79% | $10,559 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 99.38% | 96.58% | $9,938 / yr |
| 🇬🇧 UK ISA | 0% | 124.22% | 121.42% | $12,422 / yr |
| 🇬🇧 UK Taxable | 8.75% | 113.35% | 110.55% | $11,335 / yr |
| 🇨🇦 TFSA | 0% | 124.22% | 121.42% | $12,422 / yr |
| 🇨🇦 CA Taxable | 25% | 93.16% | 90.36% | $9,316 / yr |
| 🇦🇺 Super (pension) | 15% | 105.59% | 102.79% | $10,559 / yr |
| 🇦🇺 AU Taxable | 30% | 86.95% | 84.15% | $8,695 / yr |
| 🇩🇪 DE Taxable | 26.375% | 91.46% | 88.66% | $9,146 / yr |
| 🇫🇷 FR Taxable | 30% | 86.95% | 84.15% | $8,695 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 MRKR Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 MRKR Dividend Payment Schedule
MRKR pays quarterly — 4 times per year. Next ex-div: TBD.
📊 MRKR vs Healthcare Benchmarks
How MRKR compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MRKR sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ MRKR Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2025-11-17 | 137,330 | $0.95 | $131.1K | ||
| A-Award | 2025-11-17 | 84,411 | $0.95 | $80.6K | ||
| A-Award | 2025-11-17 | 137,330 | $0.95 | $131.1K | ||
| A-Award | 2025-11-17 | 84,411 | $0.95 | $80.6K | ||
| A-Award | 2025-11-17 | 137,330 | $0.95 | $131.1K | ||
| A-Award | 2025-11-17 | 84,411 | $0.95 | $80.6K | ||
| A-Award | 2025-10-31 | 147,611 | $0.99 | $145.8K | ||
| A-Award | 2025-10-31 | 250,000 | $0.99 | $246.9K | ||
| A-Award | 2025-02-12 | 30,000 | $1.59 | $47.7K | ||
| A-Award | 2025-02-12 | 30,000 | $1.59 | $47.7K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MRKR dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Marker Therapeutics, Inc. (MRKR) is currently trading at $1.61, 95% below its 52-week high. The current dividend yield is 124.22% based on an annual payout of $2.00 per share.
MRKR (Marker Therapeutics, Inc.) — 124.22% Dividend Yield Analysis
Marker Therapeutics, Inc. (MRKR) is a healthcare stock currently trading at $1.61 with a dividend yield of 124.22%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (124.22%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.